Abstract
Background: IL-23 inhibitors, risankizumab, guselkumab, and tildrakizumab, are approved systemic therapies for adults with moderate-to-severe plaque psoriasis. Although an increased risk for cerebrovascular accidents (CVAs) has been reported with exposure to combined IL-12/IL-23 inhibition in patients with cardiovascular risk, such evidence for IL-23 inhibition as monotherapy remains unaddressed. The aim of this study was to determine if a safety signal is detectable in the FAERS database for IL-23 inhibitors and subsequent CVAs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
